Aromatase in human lung carcinoma

Steroids

Volumn 76, Issue 8, 2011, Pages 759-764

  Verma, Mohit K ^a   Miki, Yasuhiro ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aromatase; Aromatase inhibitors; Estrogen receptors; Lung carcinoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AROMATASE; AROMATASE INHIBITOR; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LETROZOLE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; P90 S6 KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN SHC; RAF PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CELL LEVEL; CELL STRAIN MCF 7; CONFERENCE PAPER; CONTROLLED STUDY; DEACETYLATION; DOSE RESPONSE; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; EPIGENETICS; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSTMENOPAUSE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

AROMATASE; AROMATASE INHIBITORS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; RECEPTORS, ESTROGEN;

EID: 79958766682     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.020     Document Type: Conference Paper

References (77)

1. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008;3:819-31.
2. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 2004;291:1763-8. (Pubitemid 38489898)
3. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 2006;98:691-9. (Pubitemid 43832505)
4. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-8. (Pubitemid 350002951)
5. Pietras RJ, Márquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005;70:372-81. (Pubitemid 40616035)
6. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001;285:340-7. (Pubitemid 32918076)
7. Dabbs DJ, Landreneau RJ, Liu Y, Raab SS, Maley RH, Tung MY, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002;73:403-5.
8. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg 2002;8:69-73.
9. Schwartz G, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005;11:7280-7. (Pubitemid 41507685)
10. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005;11:5084-9. (Pubitemid 41003691)
11. Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005;130:979-86.
12. Skov BG, Fischer BM, Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008;59:88-94.
13. Niikawa H, Suzuki T, Suzuki S, Nagasaki S, Akahira J, Honma S, et al. Intratumoral estrogens and estrogen receptors in non-small cell lung carcinoma. Clin Cancer Res 2008;14:4417-26.
14. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009;27:411-7.
15. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009;15:5359-68.
16. Abe K, Miki Y, Sugawara S, Suzuki T, Sasano H. Highly concordant coexpression of aromatase and estrogen receptor β in non-small cell lung cancer. Hum Pathol 2010;41:190-8.
17. Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, et al. Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. Cancer Res 2007;67:10484-90. (Pubitemid 350070824)
18. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res 2002;62:2141-50. (Pubitemid 34408463)
19. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005;65:1598-605. (Pubitemid 40270190)
20. Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009;116:102-9.
21. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005;65:1459-70. (Pubitemid 40270175)
22. Zhang GF, Liu X, Farkas AM, Parwani AV, Lathrop KL, Lenzner D, et al. Estrogen receptor β functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 2010;24:471.
23. Márquez-Garbán DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007;72:135-43. (Pubitemid 46273500)
24. Jarzynka MJ, Bar-Joseph I, Hu B, Cheng SY. Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol 2006;28:337-44.
25. Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 2008;15:475-83. (Pubitemid 351880836)
26. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-65. (Pubitemid 27525550)
27. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ERα and ERβ. Mol Interv 2003;3:281-92.
28. Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003;17:309-17. (Pubitemid 36315626)
29. ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-300.
30. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer. Cancer Res 2001;61:5985-91.
31. Kahlert S, Nuedling S, Eickels MV, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 2000;275:18447-53. (Pubitemid 30414803)
32. Stefano GB, Prevot V, Beauvillain JC, Cadet P, Fimiani C, Welters I, et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 2000;101:1594-7. (Pubitemid 30180897)
33. Stefano GB, Cadet P, Breton C, Goumon Y, Prevot V, Dessaint JP, et al. Estradiol-stimulated nitric oxide release in human granulocytes is dependent on intracellular calcium transients: evidence of a cell surface estrogen receptor. Blood 2000;95:3951-8. (Pubitemid 30412873)
34. Watson CS, Norfleet AM, Pappas TC, Gametchu B. Rapid actions of estrogens in GH3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor-alpha. Steroids 1999;64:5-13. (Pubitemid 29172684)
35. Gustafsson JA. Estrogen receptor beta - a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379-83.
36. Canver CC, Memoli VA, Vanderveer PL, Dingivan CA, Mentzer Jr RM. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg 1994;108:153-7. (Pubitemid 24224271)
37. Kaiser U, Hofmann J, Schilli M, Wegmann B, Klotz U, Wedel S, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67:357-64. (Pubitemid 26274126)
38. Patrone C, Cassel TN, Pettersson K, Piao YS, Cheng G, Ciana P, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol 2003;23:8542-52. (Pubitemid 37441291)
39. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000;24:145-55. (Pubitemid 30117668)
40. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004;11:537-51. (Pubitemid 39331282)
41. Skliris GP, Leygue E, Watson PH, Murphy LC. Estrogen receptor α negative breast cancer patients: estrogen receptor β as a therapeutic target. J Steroid Biochem Mol Biol 2008;109:1-10.
42. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, et al. Estrogen receptorβ expression is associated with tamoxifen response in ERα-negative breast carcinoma. Clin Cancer Res 2007;13:1987-94. (Pubitemid 46649864)
43. Cheng G, Weihua Z, Warner M, Gustafsson JA. Estrogen receptors ERα and ERβ in proliferation in the rodent mammary gland. Proc Natl Acad Sci U S A 2004;101:3739-46. (Pubitemid 38386631)
44. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001;159:79-92. (Pubitemid 33704195)
45. Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, et al. Estrogen receptor β is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 2002;128:319-24. (Pubitemid 34569353)
46. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
47. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002;76:27-36. (Pubitemid 35178626)
48. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16. (Pubitemid 34498648)
49. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485-97. (Pubitemid 351880837)
50. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008;630:148-65.
51. Sasano H, Okamoto M, Mason JI, Simpson ER, Mendelson CR, Sasano N, et al. Immunolocalization of aromatase, 17alpha-hydroxylase and side-chain-cleavage cytochromes P-450 in the human ovary. J Reprod Fertil 1989;85:163-9. (Pubitemid 19040490)
52. Sasano H. Functional pathology of human ovarian steroidogenesis: normal cycling ovary and steroid-producing neoplasms. Endocr Pathol 1994;5:81-9. (Pubitemid 2096869)
53. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82. (Pubitemid 36515283)
54. Oyama T, Kagawa N, Sugio K, Uramoto H, Hatano O, Harada N, et al. Expression of aromatase CYP19 and its relationship with parameters in NSCLC. Front Biosci 2009;14:2285-92.
55. Sasano H, Suzuki T, Takeyama J, Utsunomiya H, Ito K, Ariga N, et al. 17-beta-Hydroxysteroid dehydrogenase in human breast and endometrial carcinoma. A new development in intracrinology. Oncology 2000;59:5-12.
56. Sasano H, Nagasaki S, Miki Y, Suzuki T. New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase. Ann N Y Acad Sci 2009;155:76-9.
57. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, et al. Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994;7(9):627-32. (Pubitemid 24256565)
58. Sasano H, Nagura H, Harada N, Goukon Y, Kimura M. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 1994;25:530-5. (Pubitemid 24173872)
59. Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE, Chen S. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 1992;140:337-43.
60. Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, et al. The validation of new aromatase monoclonal antibodies for immunohistochemistry - a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 2005;95:35-9. (Pubitemid 41137291)
61. Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Satao S, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol 1995;146:491-500.
62. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, et al. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 2007;67:3945-54. (Pubitemid 46762184)
63. Takahashi-Shiga N, Utsunomiya H, Miki Y, Nagase S, Kobayashi R, Matsumoto M, et al. Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions. Clin Cancer Res 2009;15:6028-34.
64. Miki Y, Suzuki T, Abe K, Suzuki S, Niikawa H, Iida S, et al. Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res 2010;70:6659-69.
65. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42. (Pubitemid 26423150)
66. Singh A, Purohit A, Ghilchik MW, Reed MJ. The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 1999;6:139-47. (Pubitemid 29260045)
67. Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 2001;142:4589-94. (Pubitemid 33022332)
68. Reed MJ, Purohit A. Aromatase regulation and breast cancer. Clin Endocrinol 2001;54:563-71. (Pubitemid 34208898)
69. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004;45:S163-75.
70. Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, et al. Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer 2009;24:109.
71. Shen H, Yuan Y, Sun J, Gao W, Shu YQ. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother 2010;64:88-92.
72. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009;64:51-9.
73. Márquez-Garbán DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci 2009;1155:194-205.
74. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
75. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005;65:11287-91. (Pubitemid 41821684)
76. Howell A, Dowsett M. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res 2004;6:269-74.
77. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. (Pubitemid 38298988)